Scientific Industries Reports Second Quarter 2024 Results
Rhea-AI Summary
Scientific Industries (OTCQB:SCND) reported financial results for Q2 2024, ending June 30. Key highlights include:
- Net revenues: $2.6M (Q2) and $5.1M (H1), down 11.2% and 12.8% YoY respectively
- Gross profit margin: 48.8% (Q2), up 350 basis points YoY
- Operating expenses decreased by 26.5% (Q2) and 22% (H1) YoY
- Net loss reduced to $1.28M (Q2) and $3.34M (H1), improvements of 44% and 28% YoY
- Cash and investments totaled $3.9M with $8.6M working capital
The company saw strong pipeline growth for Bioprocessing DOTS MPS and Torbal VIVID products, with cost-saving initiatives significantly improving financial results.
Positive
- Gross profit margin increased to 48.8% in Q2, up 350 basis points year-over-year
- Operating expenses decreased by 26.5% in Q2 and 22% in H1 compared to last year
- Net loss reduced by 44% in Q2 and 28% in H1 year-over-year
- Strong order pipelines for Bioprocessing and Torbal's VIVID product lines
- Working capital improved to $8.6 million as of June 30, 2024, up from $7.7 million last year
Negative
- Net revenues decreased by 11.2% in Q2 and 12.8% in H1 year-over-year
- Benchtop Laboratory Equipment Operations sales declined due to post-COVID destocking and market softness
- Torbal and VIVD brand products sales reduced due to new regulations affecting independent pharmacy market
News Market Reaction 1 Alert
On the day this news was published, SCND declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
STRONG PIPELINE FOR BIOPROCESSING DOTS MPS & TORBAL VIVID PILL COUNTER
OPERATIONAL EFFICIENCIES CUT QUARTER AND YTD NET LOSS BY
NET CASH USED BY OPERATIONS REDUCED BY
Investor Call to be held Thursday, August 15th at 11:00 a.m. Eastern Time
BOHEMIA, NY / ACCESSWIRE / August 15, 2024 / Scientific Industries, Inc. (OTCQB:SCND), a life sciences tool provider, and a developer of digitally simplified bioprocessing products, yesterday reported financial results for the three and six month periods ended June 30, 2024.
Business Highlights:
The Company's newly launched Bioprocessing DOTS MPS gains market traction.
The Company introduced the VIVID Workstation at major trade shows.
John Nicols, Chairman of SBI and Board member, was a guest speaker at the SynBioBeta Conference highlighting the advantages of the Company's bioprocessing products in dealing with the challenges of bioprocessing development and scale up.
Cost reduction initiatives resulted in a
44% and28% reduced net loss for the current three and six month periods against the net loss for the prior year three and six months periods.Operating cash outflow decreased significantly to
$2.4 million from$3.7 million for the same period last year.
Second Quarter and Six Months Financial Highlights:
Net revenues amounted to
$2.6 million and$5.1 million , respectively, for the three and six month periods ended June 30, 2024, compared to$3.0 million and$5.8 million in the prior year periods.Benchtop Laboratory Equipment Operations net sales were
$2.3 million and$4.4 million , compared to$2.6 million and$5.1 million in the prior year periods.Bioprocessing Systems Operations net sales were
$0.36 million and$0.68 million , compared to$0.37 million and$0.59 million in the prior year periods.
Gross profit was
$1.3 million , or48.8% and$2.3 million , or45.5% , for the three and six month periods ended June 30, 2024, compared to$1.4 million , or45.3% and$2.7 million , or46.4% in the prior year periods.Working capital was
$8.6 million as of June 30, 2024, compared to$7.7 million as of June 30, 2023.
Management Discussion
Helena Santos, Chief Executive Officer of Scientific Industries, stated, "We are optimistic as we enter the second half of 2024 with strong order pipelines for both our Bioprocessing and our Torbal's VIVID product lines, stemming from product introductions in both segments - the DOTS MPS and the VIVID WORKSTATION, which received tremendous positive feedback from customers at recent trade shows. These opportunities, together with the cost-saving initiatives that have successfully reduced cash burn and operating expenses, which led to significantly improved results, positions us well for financial stability in our core business and allow us to continue advancing our Bioprocessing strategy."
John Moore, Chairman, said, "The DOTS Multiparameter sensor launch has gone off without a hitch. In the past quarter we have sold product to some of the biggest pharma and industrial customers in the world. Our first customers have been able to integrate the DOTS MPS into their workflows and successfully complete fermentation optimization without having to scale to bioreactors thereby achieving a compelling return on investment through saving time and money. We have created the largest pipeline of sales opportunities in our company history, and we are working hard to convert it into more revenue and reference customers. We achieved an important milestone in our efforts to promote customer peer to peer sales when on August 5th a scientist from one of the world's largest pharmaceutical companies presented on his successful use of our technology at the Annual Meeting of the Society for Industrial Microbiology."
2024 First Quarter and Six Months Financial Review
Net revenues for the three and six months ended June 30, 2024 decreased
The gross profit margin for the three and six months ended June 30, 2024 was
Operating expenses decreased
As a result, the Company posted a decreased loss from continuing operations of
As of June 30, 2024, the Company's cash, cash equivalents and investments totaled
Conference Call Details
Scientific Industries will conduct a conference call to discuss financial results for the second quarter of 2024 on Thursday, August 15, 2024, at 11:00 A.M. ET. Interested parties can access the conference call by dialing (844) 481-2706 or (412) 317-0662 (international). A webcast of the call will be available on the Company's Investor Relations page at https://www.scientificindustries.com/investor-relations/ or at https://app.webinar.net/02EOnyenMPe.
A replay of the call will be available through August 23, 2024, at (877) 344-7529 or (412) 317-0088 (international), replay access code: 5275358, or for 30 days at https://www.scientificindustries.com/investor-relations/.
About Scientific Industries, Inc.
Scientific Industries (OTCQB: SCND), is a life science tool provider. It designs, manufactures, and markets laboratory equipment, including the world-renowned Vortex-Genie® 2 Mixer and Torbal® balances, and bioprocessing systems under the product name DOTS. Scientific Industries' products are generally used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies. To learn more, visit www.scientificindustries.com.
About Scientific Bioprocessing, Inc.
Scientific Bioprocessing, Inc. ("SBI") is dedicated to pioneering digitally simplified bioprocessing by providing actionable insights from lab to production floor. With a broad portfolio of state-of-the-art bioprocess sensors and actuators as well as innovative data analytics software, SBI helps scientists and engineers in bioprocessing to monitor and control critical process parameters and product quality attributes. SBI is a subsidiary of Scientific Industries Inc. (SCND-OTCQB) To learn more, visit www.scientificbio.com.
Safe Harbor Statement
Statements made in this press release that relate to future events, performance or financial results of the Company are forward-looking statements which involve uncertainties that could cause actual events, performance or results to materially differ. The Company undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statement should be read in conjunction with the additional information about risks and uncertainties set forth in the Company's Securities and Exchange Commission reports, including our annual report on Form 10-K.
Company Contact:
Helena R. Santos | or: |
---FINANCIAL TABLES FOLLOW-
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES | ||||||||
| 30-Jun-24 |
|
| 31-Dec-23 |
| |||
ASSETS |
| (Unaudited) |
|
|
|
| ||
|
|
|
|
|
| |||
Cash and Cash Equivalents |
| $ | 560,500 |
|
| $ | 796,100 |
|
Investment Securities |
|
| 3,295,100 |
|
|
| 4,928,700 |
|
Other Current Assets |
|
| 6,530,800 |
|
|
| 6,615,900 |
|
Intangibles Assets and Goodwill |
|
| 2,121,100 |
|
|
| 1,365,200 |
|
Other Long Term Assets |
|
| 1,767,500 |
|
|
| 3,024,600 |
|
Total Assets |
| $ | 14,275,000 |
|
| $ | 16,730,500 |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Current Liabilities |
| $ | 1,774,000 |
|
| $ | 1,837,300 |
|
Long-Term Liabilities |
|
| 819,400 |
|
|
| 1,007,800 |
|
Shareholders' Equity |
|
| 11,681,600 |
|
|
| 13,885,400 |
|
Total Shareholders' Equity & Liabilities |
| $ | 14,275,000 |
|
| $ | 16,730,500 |
|
|
|
|
|
|
|
|
| |
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES | ||||||||||||||||
| For the Three Months Ended |
|
| For the Six Months Ended |
| |||||||||||
| 30-Jun-24 |
|
| 30-Jun-23 |
|
| 30-Jun-24 |
|
| 30-Jun-23 |
| |||||
|
|
|
|
|
|
|
|
|
|
|
| |||||
Revenues |
| $ | 2,647,300 |
|
| $ | 2,982,500 |
|
| $ | 5,130,800 |
|
| $ | 5,787,900 |
|
Gross Profit |
|
| 1,292,400 |
|
|
| 1,350,000 |
|
|
| 2,333,200 |
|
|
| 2,688,000 |
|
Operating Expenses |
|
| 2,628,600 |
|
|
| 3,576,200 |
|
|
| 5,758,900 |
|
|
| 7,381,800 |
|
Loss From Operations |
|
| (1,336,200 | ) |
|
| (2,226,200 | ) |
|
| (3,425,700 | ) |
|
| (4,693,800 | ) |
Total Other Income, Net |
|
| 52,600 |
|
|
| 41,100 |
|
|
| 90,500 |
|
|
| 136,800 |
|
Loss From Continuing Operations Before Income Tax Expense |
|
| (1,283,600 | ) |
|
| (2,185,100 | ) |
|
| (3,335,200 | ) |
|
| (4,557,000 | ) |
Income Tax Expense |
|
| - |
|
|
| 108,800 |
|
|
| - |
|
|
| 108,800 |
|
Loss From Continuing Operations |
|
| (1,283,600 | ) |
|
| (2,293,900 | ) |
|
| (3,335,200 | ) |
|
| (4,665,800 | ) |
Gain From Discontinued Operations, Net of Tax |
|
| - |
|
|
| 1,900 |
|
|
| - |
|
|
| 3,300 |
|
Net Loss |
|
| (1,283,600 | ) |
|
| (2,292,000 | ) |
|
| (3,335,200 | ) |
|
| (4,662,500 | ) |
Comprehensive Gain (Loss) |
|
| 15,800 |
|
|
| (32,200 | ) |
|
| (44,500 | ) |
|
| 11,700 |
|
Total Comprehensive Loss |
| $ | (1,267,800 | ) |
| $ | (2,324,200 | ) |
| $ | (3,379,700 | ) |
| $ | (4,650,800 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Basic and Diluted loss per common share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Continuing Operations |
| $ | (0.12 | ) |
| $ | (0.33 | ) |
| $ | (0.32 | ) |
| $ | (0.67 | ) |
Discontinued Operations |
| $ | - |
|
| $ | - |
|
| $ | - |
|
| $ | - |
|
Consolidated Operations |
| $ | (0.12 | ) |
| $ | (0.33 | ) |
| $ | (0.32 | ) |
| $ | (0.67 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Weighted average number of outstanding shares (basic): |
|
| 10,503,599 |
|
|
| 7,003,599 |
|
|
| 10,436,647 |
|
|
| 7,003,599 |
|
SOURCE: Scientific Industries, Inc.
View the original press release on accesswire.com
FAQ
What were Scientific Industries' (SCND) Q2 2024 revenue and net loss?
How did Scientific Industries' (SCND) gross profit margin change in Q2 2024?
What new products did Scientific Industries (SCND) introduce in 2024?
How much cash and investments did Scientific Industries (SCND) have as of June 30, 2024?
